Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism.

Clinical pharmacology and therapeutics - 1 May 2007

Jones T S, Yang W, Evans W E, Relling M V

Abstract excerpt

One purpose of the International HapMap Project is to provide a genome-wide resource to discover pharmacogenetic determinants of drug response. The thiopurine methyltransferase (TPMT) 719A>G single-nucleotide polymorphism (SNP) causes decreased TPMT activity, increased intracellular thiopurines,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line
Share to Chromosome Mapping
Share to Haplotypes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isoenzymes

Share to Methyltransferases

Share to Pharmacogenetics

Share to Phenotype

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 17329987
DOI: 10.1038/sj.clpt.6100135

Genes

TPMT
HAP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17329987-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using HapMap tools in pharmacogenomic discovery: the thiopurine methyltransferase polymorphism.PMID 17329987Read ↗

Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.Semantic proximity Read ↗

Polymorphic variation in TPMT is the principal determinant of TPMT phenotype: A meta-analysis of three genome-wide association studies.Semantic proximity Read ↗

Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directionsSemantic proximity Read ↗

Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics.Semantic proximity Read ↗

PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.Semantic proximity Read ↗

TPMT gene polymorphisms: on the doorstep of personalized medicine.Semantic proximity Read ↗

Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes.Semantic proximity Read ↗

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.Semantic proximity Read ↗

Cancer pharmacogenomics: SNPs, chips, and the individual patient.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.Semantic proximity Read ↗

Advances and challenges in hereditary cancer pharmacogenetics.Semantic proximity Read ↗

Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.